Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).

Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of RK-023 for long-term use by men with pattern baldness. The other is to examine the preliminary effectiveness of this compound on hair growing. This clinical trial will be a double blind (Note 3), placebo-controlled (Note 4) study in which the study drug is applied to the scalp for 13 consecutive weeks.

"I am very pleased that early phase II clinical trial for RK-023 has started," said Dr. Yukihiko Mashima, president of R-Tech Ueno. "This is a compound that we are developing on our own for the treatment of male pattern baldness, which is part of our core dermatology operations. We plan to proceed with development activities quickly while conducting negotiations concerning alliances with companies in Japan and overseas."

R-Tech Ueno determines to complete the development of RK-023, quickly in order to provide assistance as soon as possible to men who are troubled by the loss of hair.

Notes:

  1. Androgenetic alopecia (male pattern baldness) is also called common baldness with aging. Following puberty, male hormones can prevent the regeneration of thick, long hair starting at the top of the skull and spreading forward. This hair is gradually replaced with thin, short hair. Eventually, this process leads to the atrophy of hair follicles and a decline in the number of strands of hair. Men first experience thinning of their hair and then baldness. This condition affects about 12 million men in Japan.
  2. See the R-Tech Ueno pres
    '/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015 BioElectronics Corporation (OTC Pink: BIEL), ... Therapy medical devices, announced today that its registry ... trial device has been published in the prominent ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain ... assessment.  Chronic pain is a ...
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... 4, 2015  Ironshore Pharmaceuticals & Development, Inc. ... a company specializing in personalized medicine, to participate ... designed to evaluate the safety and efficacy of ... Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s second clinical ... originally partnered with Ironshore in 2014 and continues ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:8/4/2015)... ... August 04, 2015 , ... ... Angeles commercial customers. Finding reliable hardware can be difficult and troublesome for ... putting an office together or designing a new facility, it is imperative to ...
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, Inc. announces the addition ... FACS, to its Board of Directors effective August 1, 2015. , "PerceptiMed's ... "I strongly believe in the mission of the company and the capabilities of ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent ... locations have shown a rise in binge drinking among certain populations ... and depression, are continuing to examine trends and evidence to help facilitate health ...
(Date:8/4/2015)... ... , ... 24/7 Care At Home , a provider of comprehensive home ... that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating ... on the path to meeting the aspirational goals the VA promotes each year. ...
(Date:8/4/2015)... Calif. (PRWEB) , ... August 04, 2015 , ... ... corporations, law firms and government entities, today announced that John Munro, a 15-year ... as Vice President of Managed Services Operations. , “I am thrilled to join ...
Breaking Medicine News(10 mins):Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3
... India is on the rise and is rapidly becoming the number ... spot. The seriousness of the situation is apparent after going through ... ,The rise is being documented mainly in the metros, ... areas go unnoticed. It is reported that one in 22 women ...
... The Productivity Commission of Australia has recommended a report which ... consultation with out referral from the physician. // ... report as they feel that the move will help to ... and a consultation straightly with the specialist will help the ...
... People who surf the web do not take more than ... worth it or not, according to recent scientific findings. The ... ,‘My colleagues believed it would be impossible to ... Gitte Lindgaard of Carleton University in Ottawa, who has published ...
... Medicare appears to be backfiring badly in the United States ... without essential medicines and were forced to wait for the ... citizens do not properly understand Medicare’s new prescription drug plans ... again they have no option and have to enroll themselves ...
... improvements made in diagnoses and treatment of the fatal ... a cure rate of 90%, according to researchers belonging ... ,The progressive improvement in the cure rate since ... reflects in large part the more effective use of ...
... for Health and Clinical Excellence (NICE) has found that anti-cholinesterase ... is not very effective in controlling the disease as the ... have reported that the drug action is not worth its ... one reaches forty years. Once affected, Alzheimer's gradually destroys the ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
ISI Ultra-Light Specialty Table offers the ultimate accessibility for surgeons, technicians and equipment during upper extremity surgeries....
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
Medicine Products: